We are live on ! Find out more
IOVA icon

Iovance Biotherapeutics
IOVA

269 hedge funds and large institutions have $6.9B invested in Iovance Biotherapeutics in 2020 Q4 according to their latest regulatory filings, with 57 funds opening new positions, 86 increasing their positions, 97 reducing their positions, and 39 closing their positions.

New
Increased
Maintained
Reduced
Closed

54% more call options, than puts

Call options by funds: $120M | Put options by funds: $77.8M

51% more capital invested

Capital invested by funds: $4.58B → $6.9B (+$2.32B)

46% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 39

22% more funds holding in top 10

Funds holding in top 10: 9 → 11 (+2)

7% more funds holding

Funds holding: 252 → 269 (+17)

5.83% more ownership

Funds ownership: 95.58% → 101.41% (+5.8%)

11% less repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 97

Holders
269
Holders Change
+17
Holders Change %
+6.75%
% of All Funds
4.76%
Holding in Top 10
11
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+22.22%
% of All Funds
0.19%
New
57
Increased
86
Reduced
97
Closed
39
Calls
$120M
Puts
$77.8M
Net Calls
+$42M
Net Calls Change
+$15.8M

Top Buyers

1
AIM
ARK Investment Management
Florida
+$294M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$197M
3
CCM
Consonance Capital Management
New York
+$67.9M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$53.1M
5
NAMA
Nikko Asset Management Americas
New York
+$35.9M

Top Sellers

1
GPP
Great Point Partners
Connecticut
-$117M
2
ACA
Avoro Capital Advisors
New York
-$80.8M
3
PA
Perceptive Advisors
New York
-$36.5M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$29.4M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$27.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
PF
276
Phoenix Financial
Israel
– -$3.1M -100,000 Closed
ACH
277
ArrowMark Colorado Holdings
Colorado
– -$2.56M -77,863 Closed
EAM
278
Eagle Asset Management
Florida
– -$2.06M -63,874 Closed
Marshall Wace
279
Marshall Wace
United Kingdom
– -$1.91M -58,026 Closed
LP
280
LMR Partners
United Kingdom
– -$1.63M -49,504 Closed
Group One Trading
281
Group One Trading
Illinois
– -$1.83M -46,117 Closed
MWNA
282
Marshall Wace North America
New York
– -$1.47M -44,724 Closed
CIP
283
Chartwell Investment Partners
Pennsylvania
– -$1.07M -32,633 Closed
FIA
284
FNY Investment Advisers
New York
– -$1.07M -32,500 Closed
CCMU
285
Cheyne Capital Management (UK)
United Kingdom
– -$568K -17,250 Closed
TI
286
Trexquant Investment
Connecticut
– -$551K -16,733 Closed
WCA
287
Windsor Creek Advisors
Vermont
– -$499K -15,149 Closed
Squarepoint
288
Squarepoint
New York
– -$416K -12,640 Closed
Simplex Trading
289
Simplex Trading
Illinois
– -$491K -12,359 Closed
EAM
290
Evanson Asset Management
California
– -$298K -9,050 Closed
CG
291
Cutler Group
California
– -$310K -7,809 Closed
SPC
292
Sigma Planning Corp
Michigan
– -$246K -7,461 Closed
WCM
293
Weld Capital Management
New York
– -$245K -7,441 Closed
Los Angeles Capital Management
294
Los Angeles Capital Management
California
– -$241K -7,335 Closed
B
295
Bellecapital
Switzerland
– -$228K -6,928 Closed
IWM
296
IHT Wealth Management
Illinois
– -$215K -6,541 Closed
MAM
297
Meeder Asset Management
Ohio
– -$207K -6,288 Closed
Credit Agricole
298
Credit Agricole
France
– -$198K -6,000 Closed
PCM
299
Penserra Capital Management
California
– -$41K -1,250 Closed
KBC Group
300
KBC Group
Belgium
– -$40K -1,200 Closed
9 10 11
12
13

IOVA Hedge Fund Activity: Q4 2020 in Review

269 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Iovance Biotherapeutics (IOVA) for Q4 2020, worth a combined $6.9B — up 51% from $4.58B a quarter earlier.

Buyers outnumbered sellers: 57 funds opened new IOVA positions and 39 closed out — a net gain of 18 holders — while 86 added to existing stakes and 97 trimmed.

The largest buyer was ARK Investment Management, adding an estimated $294M. The largest seller was Great Point Partners, cutting an estimated $117M.

  • 269 institutional investors held Iovance Biotherapeutics (IOVA) as of Q4 2020, up from 252 in Q3 2020.
  • Funds reported $6.9B of Iovance Biotherapeutics stock for Q4 2020, up 51% quarter-over-quarter.
  • 57 funds opened new Iovance Biotherapeutics positions in Q4 2020 and 39 closed out, a net change of +18 holders.
  • The largest Iovance Biotherapeutics buyer in Q4 2020 was ARK Investment Management, an estimated $294M added.
  • The largest Iovance Biotherapeutics seller in Q4 2020 was Great Point Partners, an estimated $117M sold.

Based on aggregated 13F filings for Q4 2020.